多发性硬化症的治疗转换：有哪些选择？ - Suppr

Switching therapies in MS: what are the options?

作者信息

Markowitz Clyde E

机构信息

From the Department of Neurology and the Multiple Sclerosis Center, the Hospital of the University of Pennsylvania, Philadelphia.

出版信息

J Clin Psychiatry. 2015 Feb;76(2):e6. doi: 10.4088/JCP.13037nr2c.

DOI:10.4088/JCP.13037nr2c

PMID:25742221

Abstract

摘要

相似文献

Switching therapies in MS: what are the options?

J Clin Psychiatry. 2015 Feb;76(2):e6. doi: 10.4088/JCP.13037nr2c.

Risk stratification and mitigation multiple sclerosis.

Mult Scler Relat Disord. 2014 Sep;3(5):639-49. doi: 10.1016/j.msard.2014.05.003.

Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.

Neuroimaging Clin N Am. 2017 May;27(2):195-204. doi: 10.1016/j.nic.2016.12.001.

[New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].

Ideggyogy Sz. 2012 Nov 30;65(11-12):421-2.

A practical guide to pediatric multiple sclerosis.

Neuropediatrics. 2010 Aug;41(4):157-62. doi: 10.1055/s-0030-1267155. Epub 2010 Nov 17.

Managing Risks with Immune Therapies in Multiple Sclerosis.

Drug Saf. 2019 May;42(5):633-647. doi: 10.1007/s40264-018-0782-8.

The use of disease-modifying agents in multiple sclerosis--by the Canadian Network of MS Clinics.

Can J Neurol Sci. 2008 May;35(2):127-32.

A changing treatment landscape for multiple sclerosis: challenges and opportunities.

J Intern Med. 2014 Apr;275(4):364-81. doi: 10.1111/joim.12204. Epub 2014 Mar 17.

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.

Adv Ther. 2011 Jan;28(1):51-61. doi: 10.1007/s12325-010-0093-7. Epub 2010 Dec 6.

Multiple sclerosis: new insights in pathogenesis and novel therapeutics.

Annu Rev Med. 2012;63:389-404. doi: 10.1146/annurev-med-042910-135833. Epub 2011 Sep 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Switching therapies in MS: what are the options?

J Clin Psychiatry. 2015 Feb;76(2):e6. doi: 10.4088/JCP.13037nr2c.

Risk stratification and mitigation multiple sclerosis.

Mult Scler Relat Disord. 2014 Sep;3(5):639-49. doi: 10.1016/j.msard.2014.05.003.

Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.

Neuroimaging Clin N Am. 2017 May;27(2):195-204. doi: 10.1016/j.nic.2016.12.001.

[New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].

Ideggyogy Sz. 2012 Nov 30;65(11-12):421-2.

A practical guide to pediatric multiple sclerosis.

Neuropediatrics. 2010 Aug;41(4):157-62. doi: 10.1055/s-0030-1267155. Epub 2010 Nov 17.

Managing Risks with Immune Therapies in Multiple Sclerosis.

Drug Saf. 2019 May;42(5):633-647. doi: 10.1007/s40264-018-0782-8.

The use of disease-modifying agents in multiple sclerosis--by the Canadian Network of MS Clinics.

Can J Neurol Sci. 2008 May;35(2):127-32.

A changing treatment landscape for multiple sclerosis: challenges and opportunities.

J Intern Med. 2014 Apr;275(4):364-81. doi: 10.1111/joim.12204. Epub 2014 Mar 17.

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.

Adv Ther. 2011 Jan;28(1):51-61. doi: 10.1007/s12325-010-0093-7. Epub 2010 Dec 6.

Multiple sclerosis: new insights in pathogenesis and novel therapeutics.

Annu Rev Med. 2012;63:389-404. doi: 10.1146/annurev-med-042910-135833. Epub 2011 Sep 1.

Switching therapies in MS: what are the options?

作者信息

机构信息

出版信息

相似文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

Switching therapies in MS: what are the options?

作者信息

机构信息

出版信息